InvestSMART

Clarity Pharmaceuticals Ltd (ASX: CU6) - Announcements

Current share price for CU6 : $1.770 0.02 (1.12%)+

ASX company news and announcements for Clarity Pharmaceuticals Ltd (CU6) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clarity Pharmaceuticals Ltd (CU6) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clarity Pharmaceuticals Ltd (CU6), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clarity Pharmaceuticals Ltd (CU6)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$660 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2025 3:06PM $2.200 $1.770 fallen by 19.55%
$660 Change in substantial holding 22 Apr 2025 6:51PM $1.805 $1.770 fallen by 1.94%
$660 Ceasing to be a substantial holder 17 Apr 2025 4:33PM $1.900 $1.770 fallen by 6.84%
$660 Clarity signs commercial-scale copper-64 Supply Agreement 17 Apr 2025 9:55AM $1.680 $1.770 risen by 5.36%
$660 $11.1 million RDTI and refocus on high-priority programs 17 Apr 2025 9:53AM $1.680 $1.770 risen by 5.36%
$660 Becoming a substantial holder 16 Apr 2025 3:43PM $1.695 $1.770 risen by 4.42%
$660 First patient treated in the Phase II of the SECuRE trial 15 Apr 2025 9:40AM $1.745 $1.770 risen by 1.43%
$660 Change of Registered Office and Registry Address 14 Apr 2025 10:01AM $1.680 $1.770 risen by 5.36%
$660 Becoming a substantial holder 11 Apr 2025 8:21AM $1.655 $1.770 risen by 6.95%
$660 Notification of cessation of securities - CU6 10 Apr 2025 5:18PM $1.655 $1.770 risen by 6.95%
$660 Becoming a substantial holder 9 Apr 2025 6:26PM $1.460 $1.770 risen by 21.23%
$660 Cleansing Notice 5 Mar 2025 1:57PM $3.100 $1.770 fallen by 42.90%
$660 Application for quotation of securities - CU6 5 Mar 2025 1:51PM $3.100 $1.770 fallen by 42.90%
$660 Clarity signs Cu-64 Supply Agreement with UQ 5 Mar 2025 9:57AM $2.970 $1.770 fallen by 40.40%
$660 SECuRE trial update 5 Mar 2025 9:55AM $2.970 $1.770 fallen by 40.40%
$660 Half Yearly Report and Accounts 28 Feb 2025 3:52PM $3.540 $1.770 fallen by 50%
$660 Appendix 4D 28 Feb 2025 3:52PM $3.540 $1.770 fallen by 50%
$660 Clarity receives US FDA FTD for the treatment of mCRPC 19 Feb 2025 9:31AM $3.380 $1.770 fallen by 47.63%
$660 Response to ASX Cleansing Notice Timing Letter 18 Feb 2025 11:04AM $3.310 $1.770 fallen by 46.53%
$660 Cleansing Notice 11 Feb 2025 2:00PM $3.440 $1.770 fallen by 48.55%
$660 Application for quotation of securities - CU6 11 Feb 2025 1:53PM $3.425 $1.770 fallen by 48.32%
$660 Clarity expands pipeline with Cu-64/67 SAR-trastuzumab 11 Feb 2025 9:40AM $3.640 $1.770 fallen by 51.37%
$660 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2025 11:57AM $3.755 $1.770 fallen by 52.86%
$660 Cleansing Notice 29 Jan 2025 6:54PM $4.050 $1.770 fallen by 56.30%
$660 Application for quotation of securities - CU6 29 Jan 2025 6:48PM $4.050 $1.770 fallen by 56.30%

151 - 175 of 521 results

Page 7 of 21

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.